Results 51 to 60 of about 2,457 (125)

Evaluation of the Effectiveness of Using the CFTR Modulator Ivacaftor/Lumacaftor in Children with Cystic Fibrosis in the Sverdlovsk Region (Prospective Cohort Study)

Педиатрическая фармакология
Background. A modern achievement in the treatment of cystic fibrosis has been the discovery of small molecules that restore the processes of synthesis, transport to the membrane, and the work of the defective CFTR protein.
Yuliya O. Vasenyova, Irina V. Vakhlova, Oleg Yu. Averyanov   +2 more
doaj   +1 more source

Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma

International Medical Case Reports Journal, 2017
Saqib Walayat,1 Nooreen Hussain,1 Jaymon Patel,1 Faiz Hussain,2 Preeti Patel,1 Sonu Dhillon,1 Bhagat Aulakh,3,4 Subramanyam Chittivelu3 1Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, 2Department of ...
Walayat S, Hussain N, Patel J, Hussain F, Patel P, Dhillon S, Aulakh B, Chittivelu S   +7 more
doaj  

Post-marketing safety profile of lumacaftor/ivacaftor in cystic fibrosis treatment: a pharmacovigilance analysis based on FAERS. [PDF]

Front Med (Lausanne)
Wang T, Yang W, Luo Y, Zhan Y, Zou F, Cui Z, Lan Y.   +6 more
europepmc   +1 more source

Greenness, Whiteness, and Blueness Assessment With a Novel and Fully Validated HPLC Method for Simultaneous Analysis of Lumacaftor and Ivacaftor in Sweat. [PDF]

Int J Anal Chem
Levent S, Elriş A, Özcan S, Can NÖ.
europepmc   +1 more source

Functional, Cohort-Level Assessment of CFTR Modulator Responses Using Biobanked Nasal Epithelial Cells from Individuals with Cystic Fibrosis. [PDF]

J Pers Med
Aalbers BL, Amatngalim GD, Aarts EM, Rodenburg LW, den Hertog-Oosterhoff LA, Heijerman HGM, Beekman JM.   +6 more
europepmc   +1 more source

Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator. [PDF]

Am J Physiol Lung Cell Mol Physiol
Ambrosetti AD, Hagedorn ZJ, Bono TR, Wen H, Nguyen R, Rodriguez-Cruz K, Ali J, Palacio H, Phillips AJ, Gilliland SD, Freeman AJ, Thompson J, Fu L, McNicholas CM, Rowe SM, Wang XR.   +15 more
europepmc   +1 more source

Comparative efficacy and safety of CFTR modulators for people with cystic fibrosis with phe508del mutation: a systematic review and bayesian network meta-analysis. [PDF]

EClinicalMedicine
Safeer V S M, Behl S, Vaidya PC, Tiwari P, Bharti SK, Nahan N, Kumar Sahu J, Bansal D.   +7 more
europepmc   +1 more source

Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis. [PDF]

Gastro Hep Adv
Vongsavath T, Tun KM, Mukhopadhyay D, Lo CH, Singh A, Amin R, Twohig P, Saab S, Manne V.   +8 more
europepmc   +1 more source

The effect of elexacaftor-tezacaftor-ivacaftor on liver stiffness in children with cystic fibrosis. [PDF]

J Pediatr Gastroenterol Nutr
Diemer S, Elidottir H, Eklund EA, Påhlman LI, Hansen C.   +4 more
europepmc   +1 more source

Improvement of Cystic Fibrosis-Associated Liver Disease in Adults on Long-Term Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. [PDF]

Life (Basel)
Manioudaki S, Vasilieva L, Geladari E, Mani I, Athanassa Z, Elefsiniotis I, Hadziyannis E, Sevastianos V, Oikonomou A, Theophilou A, Diamantea F, Alexopoulou A.   +11 more
europepmc   +1 more source